Halozyme Therapeutics, Inc. $HALO Shares Newly Bought by Monument Capital Management

Monument Capital Management acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 28,511 shares of the biopharmaceutical company’s stock, valued at approximately $3,148,000.

A number of other hedge funds also recently bought and sold shares of HALO. CoreCap Advisors LLC increased its position in shares of Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares in the last quarter. Twin Capital Management Inc. boosted its stake in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 161 shares during the period. First Citizens Bank & Trust Co. boosted its stake in Halozyme Therapeutics by 2.0% in the 1st quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 175 shares during the period. Nations Financial Group Inc. IA ADV grew its position in Halozyme Therapeutics by 1.2% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock worth $981,000 after purchasing an additional 183 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its position in Halozyme Therapeutics by 0.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company’s stock worth $1,640,000 after purchasing an additional 202 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HALO. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. HC Wainwright lifted their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, TD Cowen raised their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: A Dutch patent court ruled that Merck’s subcutaneous Keytruda infringes a Halozyme patent and ordered MSD to stop manufacturing, selling, importing, or stocking the product in eight European markets. The injunction strengthens Halozyme’s intellectual-property position and could help protect future royalty opportunities. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck’s Keytruda SC in Multiple European Markets
• Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to include two additional exclusive targets, bringing the total to eight. The deal expands the potential for development milestones, licensing payments, and royalties while supporting long-term revenue growth. HALO Expands ENHANZE Collaboration and Licensing Deal With argenx
• Neutral Sentiment: Halozyme CEO Helen Torley sold 20,000 shares for approximately $2.19 million at an average price of $109.40, reducing her holdings by 2.54%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary signal about management’s outlook. Halozyme Therapeutics CEO Helen Torley Sells 20,000 Shares
• Negative Sentiment: JPMorgan raised its price target for HALO from $70 to $78 but retained a “neutral” rating. The target remains substantially below the referenced $109.84 share price, suggesting the bank believes the stock’s legal and growth prospects may already be reflected in its valuation. JPMorgan Raises Halozyme Price Target

Halozyme Therapeutics Stock Down 0.9%

HALO stock opened at $109.84 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $116.85. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market cap of $12.47 billion, a price-to-earnings ratio of 32.79, a PEG ratio of 0.42 and a beta of 0.88. The company has a 50 day moving average of $105.64 and a two-hundred day moving average of $82.86.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same period in the previous year, the company posted $1.54 EPS. Halozyme Therapeutics’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 5,230 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director directly owned 53,609 shares in the company, valued at approximately $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 125,852 shares of company stock valued at $13,538,046. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.